CareyHwangMDPhD

Infectious Disease • Skillman, NJ

HIV/AIDS Medicine

Senior Vice President, Clinical Research, Head of Chronic Infection - Vir Biotechnology

Join to view full profile

Dr. Hwang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hwang's full profile

Already have an account?

Office
241 Sunset Rd
Skillman, NJ 08558
Phone+1 415-992-6293

Education & Training

Vanderbilt University Medical CenterFellowship, Infectious Disease, 2005 - 2009
Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2005
West Virginia University School of MedicineClass of 2003

Certifications & Licensure

TN State Medical License 2004 - 2019

Clinical Trials

HIV Resistance and Treatment Strategies Start of enrollment: 2007 Jan 01
Completed

Publications & Presentations

PubMed

23 citations
An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects
Marc Bifano, Robert Adamczyk, Carey Hwang, Hamza Kandoussi, Alan Marion
Clinical Drug Investigation. 2015-04-21
50 citations
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority...
Jean-Michel Molina, Kathleen Squires, Paul E. Sax, Pedro Cahn, Johan Lombaard
The Lancet. HIV. 2020-01-01
41 citations
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-66...
Neelanjana Ray, Carey Hwang, Matthew D. Healy, Jeannette M. Whitcomb, Max Lataillade
Journal of Acquired Immune Deficiency Syndromes. 2013-09-01

Journal Articles

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...
George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases

Press Mentions

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus InfectionSeptember 22nd, 2022
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver ConferenceJune 27th, 2022
Vir Biotechnology Announces New Clinical Data from Its Broad Hepatitis B ProgramJune 27th, 2022
Join now to see all